As an example, 1 question asked about a treatment recommendation for a patient diagnosed with metastatic right-sided colon cancer with a BRAF V600E variant who achieved a partial response to 5-fluorouracil, oxaliplatin, and bevacizumab but also developed peripheral sensory neuropathy. This evidence concerns the gene BRAF and sensory peripheral neuropathy.